Novartis

GSK seeks mid-September bids for $4 billion Indian Horlicks unit, say sources

GSK started a strategic review of Horlicks - a malt-based drink brand popular in India – and some smaller products, after buying Novartis out of their consumer healthcare venture for $13 billion in March.

GSK to sell Horlicks to fund $13 bn Novartis deal; Nestle, Kraft, Unilever likely suitors, say sources

GSK has started a strategic review of Horlicks - a malt-based drink brand popular in India – and some of its smaller products, after buying Novartis out of their consumer healthcare venture for $13 billion on Tuesday.

Novartis CEO Narasimhan rehauls co leadership as operations president Andre Wyss exits

Novartis’ new Chief Executive Vas Narasimhan is remaking the Swiss drugmaker’s leadership as operations president Andre Wyss exits

Free diagnostic camps seek to revolutionise healthcare in rural India, but affordability of medicines affecting impact

However, free diagnosis solves only a part of the problem for these villagers.

ISB sees 39% rise in campus placements with 1,113 offers, average salary at Rs 22 lakh

Over 70 offers were made to ISB students for leadership roles by leading corporates including Aditya Birla Group, Citibank, Yes Bank, Philips India Ltd, Tech Mahindra, MAX, Mytrah Energy and Genpact.

Google to bet on Euro biotech company to deliver life-changing drugs

The move shows Google pumping cash into global medical research, seeding what it believes will become a core long-term healthcare business.

Novartis backs out of human testing of Google autofocus contact lens in 2016

Novartis has abandoned a 2016 goal to start testing its autofocus contact lens on people, though it said the groundbreaking product it is making with internet giant Google is "progressing steadily."

Sun Pharma inks distribution alliance with Mitsubishi Tanabe for 14 brands

These 14 prescription brands acquired by the company earlier this year will be transferred from Novartis Pharma K.K. to Sun Pharma's subsidiary in Japan beginning October 2016

Prices of cancer, diabetes, blood pressure drugs slashed by 25%

Prices of 56 important drugs used in treatment of cancer, diabetes, bacterial infections and blood pressure have been capped by the government thereby reducing the cost by an average of around 25 percent.

Prices of 56 drugs to come down; NPPA fixes ceiling rates

Prices may come down of 56 important medicines used in treatment of cancer, diabetes, bacterial infections and high blood pressure, with the government fixing their ceiling prices under the drug pricing control mechanism.